Skip to main content
. 2021 Aug 21;22:231. doi: 10.1186/s12931-021-01827-4

Table 3.

Comparisons of responses to iEPO between high and low concentration delivery strategies

iEPO indications High concentration delivery Low concentration delivery p
Pre Post p Pre Post p
Overall
 HR, beats/min 101.6 ± 20.7 100.7 ± 21.2 0.496 103.9 ± 19.6 102.7 ± 18.9 0.301 0.949
 RR, breaths/min 24.0 ± 7.4 24.1 ± 6.4 0.923 25.5 ± 7.4 25.1 ± 7.3 0.373 0.964
 mBP, mm Hg 77.3 (69.3, 85) 75.0 (68.0, 84.0) 0.158 74 (67.8, 84.5) 75 (70.0, 82.2) 0.669 0.773
Hypoxemia (n = 58 high concentration vs 56 low concentration)
 SpO2/FIO2 89.5 (84, 102.5) 99 (91.8, 134.6) < 0.001 93.5 (88, 106.4) 98.5(93, 121.3) < 0.001 0.436
 PaO2/FIO2, mm Hga 67(57, 101.4) 113.3 (78.9, 169.2) < 0.001 73 (59, 88.8) 107.5 (77.8, 148.3) < 0.001 0.948
 PEEP, cm H2O 13.0 ± 4.2 13.3 ± 4.6 0.403 13.2 ± 5.0 12.9 ± 4.6 0.263 0.197
Pulmonary hypertension (n = 30 high concentration vs 25 low concentration)
 mPAP, mmHgb 39.1 ± 11.6 34.5 ± 10.3 0.012 36.7 ± 9.0 31.7 ± 7.3 0.019 0.551
 CO, L/minc 4.2 ± 0.5 5.3 ± 1.1 0.003 6.3 ± 2.1 6.0 ± 1.8 0.635 0.337
 CI, L/min/m2 d 2.22 ± 0.32 2.75 ± 0.70 0.006 3.23 ± 1.24 2.97 ± 0.92 0.593 0.231
 SvO2, %e 65.6 ± 15.5 67.1 ± 15.4 0.131 65.2 ± 12.2 64.9 ± 8.3 1.0 0.429
Right heart failure (n = 20 high concentration vs 14 low concentration)
 mPAP, mmHgf 33.4 ± 14 29.8 ± 10.3 0.094 29.9 ± 7.1 27.6 ± 3.8 0.283 0.979
 CO, L/ming 4.4 ± 0.6 5.5 ± 1.1 0.011 6.2 ± 3.1 6.2 ± 2.4 1.0 0.359
 CI, L/min/m2 h 2.32 ± 0.37 2.89 ± 0.56 0.008 3.20 ± 2.06 2.95 ± 1.32 0.606 0.141
 SvO2, %i 67.2 ± 10.8 68.2 ± 10.5 0.426 67.8 ± 14.7 65.8 ± 13.4 0.236 0.142

iEPO inhaled epoprostenol, HR heart rate, RR respiratory rate, mBP mean blood pressure, mPAP mean pulmonary arterial pressure, SpO2 saturation of pulse oximetry, FIO2 fraction of inspired oxygen, PaO2 partial pressure of arterial oxygen, PEEP positive end expiratory pressure, CO cardiac output, CI cardiac index, SvO2 saturation of mixed venous oxygen

aData was available in 45 and 35 patients in intermittent and continuous delivery group, respectively

bData was available in 22, 15 patients in two groups

cData was available in 12, 9 patients in two groups

dData was available in 13, 9 patients in two groups

eData was available in 7, 10 patients in two groups

fData was available in 14, 7 patients in two groups

gData was available in 8, 4 patients in two groups

hData was available in 9, 4 patients in two groups

iData was available in 6, 4 patients in two groups